Use of High-Frequency 10-kHz Spinal Cord Stimulation in the Treatment of Persistent Spinal Pain Syndrome Type 2: A Systematic Review.

IF 3.5 3区医学 Q2 CLINICAL NEUROLOGY

Neuromodulation Pub Date : 2025-10-17 DOI:10.1016/j.neurom.2025.08.417

Saiganesh Ravikumar, Brandon Stevens, Te'Amrat Mehreteab, Michael Erdek

{"title":"Use of High-Frequency 10-kHz Spinal Cord Stimulation in the Treatment of Persistent Spinal Pain Syndrome Type 2: A Systematic Review.","authors":"Saiganesh Ravikumar, Brandon Stevens, Te'Amrat Mehreteab, Michael Erdek","doi":"10.1016/j.neurom.2025.08.417","DOIUrl":null,"url":null,"abstract":"Objectives: In 2015, 10-kHz high-frequency (10-kHz) spinal cord stimulation (SCS) received Food and Drug Administration approval to treat persistent spinal pain syndrome type 2 (PSPS-2). The outcomes of 10-kHz SCS on PSPS-2 have not been systematically reviewed. We systematically reviewed the relevant literature and hypothesized that 10-kHz SCS is safe and effective in managing pain in patients with PSPS-2.Materials and methods: PUBMED and EMBASE data bases were searched with the query ((spinal cord stimulator) OR (spinal cord stimulation) OR (SCS)) AND (pain) AND ((10 khz) OR (10-khz) OR (HF10) OR (HF-10)) on April 24, 2024.Results: The search produced 636 nonduplicate articles. After applying the inclusion/exclusion criteria, nine studies were selected. Seven studies reported the percentage passing 10-kHz SCS trial, and the weighted average based on the number of patients was 87.3% success rate overall. Three studies measured overall pain on the visual analog scale (VAS), and six measured VAS back and leg separately. The weighted average for VAS overall, back, and leg was 8.1 (preoperation), 4.7 (postoperation); 7.0 (preoperation), 2.0 (postoperation); and 5.7 (preoperation), 1.6 (postoperation), respectively. Two studies evaluated the Beck Depression Index, and the weighted average was 23.8 (preoperation) and 14.0 (postoperation). Three studies evaluated the Oswestry Disability Index (ODI), and the weighted average was 48.3 (preoperation) and 30.6 (postoperation). Two studies compared burst stimulation with 10-kHz SCS, and both found no difference in back pain scores, whereas both studies found greater improvement in leg pain in the burst groups. Two studies compared low-frequency SCS with 10-kHz SCS, and both studies found no significant difference in VAS or ODI scores between the two treatments. There were no reported unanticipated adverse device effects across the studies.Conclusion: For many patients with refractory PSPS-2, 10-kHz SCS is a safe, effective treatment, but there is a lack of evidence of its superiority to burst or traditional SCS.","PeriodicalId":19152,"journal":{"name":"Neuromodulation","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuromodulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.neurom.2025.08.417","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: In 2015, 10-kHz high-frequency (10-kHz) spinal cord stimulation (SCS) received Food and Drug Administration approval to treat persistent spinal pain syndrome type 2 (PSPS-2). The outcomes of 10-kHz SCS on PSPS-2 have not been systematically reviewed. We systematically reviewed the relevant literature and hypothesized that 10-kHz SCS is safe and effective in managing pain in patients with PSPS-2.

Materials and methods: PUBMED and EMBASE data bases were searched with the query ((spinal cord stimulator) OR (spinal cord stimulation) OR (SCS)) AND (pain) AND ((10 khz) OR (10-khz) OR (HF10) OR (HF-10)) on April 24, 2024.

Results: The search produced 636 nonduplicate articles. After applying the inclusion/exclusion criteria, nine studies were selected. Seven studies reported the percentage passing 10-kHz SCS trial, and the weighted average based on the number of patients was 87.3% success rate overall. Three studies measured overall pain on the visual analog scale (VAS), and six measured VAS back and leg separately. The weighted average for VAS overall, back, and leg was 8.1 (preoperation), 4.7 (postoperation); 7.0 (preoperation), 2.0 (postoperation); and 5.7 (preoperation), 1.6 (postoperation), respectively. Two studies evaluated the Beck Depression Index, and the weighted average was 23.8 (preoperation) and 14.0 (postoperation). Three studies evaluated the Oswestry Disability Index (ODI), and the weighted average was 48.3 (preoperation) and 30.6 (postoperation). Two studies compared burst stimulation with 10-kHz SCS, and both found no difference in back pain scores, whereas both studies found greater improvement in leg pain in the burst groups. Two studies compared low-frequency SCS with 10-kHz SCS, and both studies found no significant difference in VAS or ODI scores between the two treatments. There were no reported unanticipated adverse device effects across the studies.

Conclusion: For many patients with refractory PSPS-2, 10-kHz SCS is a safe, effective treatment, but there is a lack of evidence of its superiority to burst or traditional SCS.

查看原文本刊更多论文

使用高频10khz脊髓刺激治疗2型持续性脊柱疼痛综合征：系统综述。

2015年，10 khz高频（10 khz）脊髓刺激（SCS）获得美国食品和药物管理局（fda）批准，用于治疗2型持续性脊柱疼痛综合征（PSPS-2）。10khz SCS对pps -2的效果尚未系统回顾。我们系统地回顾了相关文献，并假设10khz SCS在治疗PSPS-2患者疼痛方面是安全有效的。材料和方法：于2024年4月24日检索PUBMED和EMBASE数据库，检索条件为((spinal cord stimulator) OR (spinal cord stimulation) OR (SCS) and (pain) and ((10khz) OR (10khz) OR （HF10) OR (HF-10)）。结果：搜索产生了636篇不重复的文章。应用纳入/排除标准后，选择了9项研究。7项研究报告了10-kHz SCS试验的通过率，基于患者数量的加权平均成功率为87.3%。3项研究用视觉模拟量表（VAS）测量总体疼痛，6项研究分别测量背部和腿部的VAS。VAS总体、背部和腿部加权平均值分别为8.1（术前）、4.7（术后）；7.0（术前），2.0（术后）；术前5.7分，术后1.6分。两项研究评估了贝克抑郁指数，加权平均值分别为23.8（术前）和14.0（术后）。3项研究评估了Oswestry残疾指数（ODI），加权平均值分别为术前48.3和术后30.6。两项研究比较了爆发刺激和10 khz SCS，都发现背部疼痛评分没有差异，而两项研究都发现爆发组在腿部疼痛方面有更大的改善。两项研究比较了低频SCS和10khz SCS，两项研究均发现两种治疗之间的VAS或ODI评分无显著差异。在所有的研究中都没有发现意想不到的不良反应。结论：对于许多难治性PSPS-2患者，10khz SCS是一种安全、有效的治疗方法，但缺乏证据表明其优于burst或传统SCS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuromodulation 医学-临床神经学

CiteScore

6.40

自引率

3.60%

发文量

978

审稿时长

54 days

期刊介绍： Neuromodulation: Technology at the Neural Interface is the preeminent journal in the area of neuromodulation, providing our readership with the state of the art clinical, translational, and basic science research in the field. For clinicians, engineers, scientists and members of the biotechnology industry alike, Neuromodulation provides timely and rigorously peer-reviewed articles on the technology, science, and clinical application of devices that interface with the nervous system to treat disease and improve function.